Advertisement
U.S. markets closed
  • S&P Futures

    5,304.25
    -4.00 (-0.08%)
     
  • Dow Futures

    40,140.00
    -36.00 (-0.09%)
     
  • Nasdaq Futures

    18,465.00
    -38.75 (-0.21%)
     
  • Russell 2000 Futures

    2,145.20
    +6.80 (+0.32%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0781
    -0.0013 (-0.12%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • Vix

    13.01
    +0.23 (+1.80%)
     
  • GBP/USD

    1.2622
    -0.0000 (-0.00%)
     
  • USD/JPY

    151.2850
    -0.0870 (-0.06%)
     
  • Bitcoin USD

    70,786.20
    +1,302.95 (+1.88%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,402.47
    +234.40 (+0.58%)
     

Is There An Opportunity With BioLife Solutions Inc’s (NASDAQ:BLFS) 21.60% Undervaluation?

I am going to run you through how I calculated the intrinsic value of BioLife Solutions Inc (NASDAQ:BLFS) using the discounted cash flow (DCF) method. Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model. Also note that this article was written in January 2018 so be sure check the latest calculation for BioLife Solutions here.

Is BLFS fairly valued?

We are going to use a two-stage DCF model, which simply means we have two different periods of varying growth rates for the company’s cash flows. Generally the initial phase has higher growth rates that plateau over time. To start off, I took the analyst consensus estimates of BLFS’s levered free cash flow (FCF) over the next five years and discounted these values at the cost of equity of 8.49%. When estimates weren’t available, I’ve extrapolated the average annual growth rate over the previous five years, capped at a reasonable level. This resulted in a present value of 5-year cash flow of $17.8M. Keen to understand how I calculated this value? Check out our detailed analysis here.

NasdaqCM:BLFS Intrinsic Value Jan 5th 18
NasdaqCM:BLFS Intrinsic Value Jan 5th 18

The graph above shows how BLFS’s top and bottom lines are expected to move going forward, which should give you an idea of BLFS’s outlook. Next, I determine the terminal value, which is the business’s cash flow after the first stage. I’ve decided to use the 10-year government bond rate of 2.8% as the perpetual growth rate, which is rightly below GDP growth, but more towards the conservative side. After discounting the terminal value back five years, the present value becomes $83.9M.

The total value is the sum of cash flows for the next five years and the discounted terminal value, which results in the Total Equity Value, which in this case is $101.7M. To get the intrinsic value per share, we divide this by the total number of shares outstanding. This results in an intrinsic value of $7.46, which, compared to the current share price of $5.85, we find that BioLife Solutions is about right, perhaps slightly undervalued at a 21.60% discount to what it is available for right now.

Next Steps:

Whilst important, DCF calculation shouldn’t be the only metric you look at when researching a company. What is the reason for the share price to differ from the intrinsic value? For BLFS, I’ve put together three relevant aspects you should further research:

PS. The Simply Wall St app conducts a discounted cash flow for every stock on the NASDAQ every 6 hours. If you want to find the calculation for other stocks just search here.


To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned.

Advertisement